Interim Report 1 January to 31 March 2020
Summary of the interim reportFirst Quarter (1 January to 31 March 2020) · Operating revenue KSEK 0 (0) · Income after financial items KSEK -10 183 (-6 757) · Earnings per share -0,21 (-0,18) · Cash and cash equivalents as of 31 March KSEK 51 831 (30 049) · Equity ratio as of 31 March 95,5 (90,3) % Significant events during the first quarter of 2020 · Cyxone announced in January that the company has ordered more Rabeximod substance earlier than planned. As a result, the first patient in the clinical Phase IIb trial is expected to be dosed in the first quarter of 2021.